Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development
1997

Topoisomerase I Inhibitors and Prolonged Exposure in Cancer Treatment

Sample size: 52 publication Evidence: moderate

Author Information

Author(s): CJH Gerrits, MJA de Jonge, JHM Schellens, G Stoter, J Verweij

Primary Institution: Rotterdam Cancer Institute and University Hospital, Rotterdam, The Netherlands

Hypothesis

Prolonged exposure to topoisomerase I inhibitors may enhance their anti-tumor activity compared to short-term exposure.

Conclusion

Prolonged exposure to topoisomerase I inhibitors is suggested to be relevant for anti-tumor activity, but optimal schedules are still to be determined.

Supporting Evidence

  • Topoisomerase I inhibitors have shown anti-tumor activity in various cancers.
  • Prolonged exposure may be more effective than short-term high-dose exposure.
  • Clinical data on the efficacy of prolonged exposure are still developing.

Takeaway

This study looks at how giving cancer drugs for a longer time might work better than giving a lot of the drug all at once.

Methodology

The review summarizes preclinical and clinical studies on topoisomerase I inhibitors, focusing on their efficacy with prolonged exposure.

Limitations

Clinical data are too immature to draw definitive conclusions about the optimal treatment schedules.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication